Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Hugues Chanteux"'
Autor:
Karelle Ménochet, Hugues Chanteux, Jamie Henshall, Jean‐Marie Nicolas, Sara Wright, Judith Asperen, Anna‐Lena Ungell
Publikováno v:
Oral Drug Delivery for Modified Release Formulations. :39-64
Autor:
Tamara D. Cabalu, Mengyao Li, Kenichi Umehara, Dermot F. McGinnity, Neil Parrott, Kunal S Taskar, Arian Emami Riedmaier, Micaela B Reddy, Hugues Chanteux, Martin E. Dowty, Justine Badée, Jialin Mao, Jayaprakasam Bolleddula, Loeckie de Zwart, Jessica Rehmel, Dwaipayan Mukherjee, Chandra Prakash, Niresh Hariparsad, Masakatsu Kotsuma, Diane Ramsden, Karthik Venkatakrishnan, Venkatesh Pilla Reddy, Kushal Shah
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:770-781
The International Consortium for Innovation and Quality (IQ) Physiologically Based Pharmacokinetic (PBPK) Modeling Induction Working Group (IWG) conducted a survey across participating companies around general strategies for PBPK modeling of inductio
Publikováno v:
Journal of Medicinal Chemistry. 64:6413-6522
This perspective discusses the role of pregnane xenobiotic receptor (PXR) in drug discovery and the impact of its activation on CYP3A4 induction. The use of structural biology to reduce PXR activity on drug discovery projects has become more common i
Autor:
Johan Nicolaï, Khaled Abduljalil, Trevor N. Johnson, Pierandrea Muglia, Hugues Chanteux, David G. Sciberras, Miranda Cornet, Eric Gillent, Jean-Marie Nicolas
Publikováno v:
British Journal of Clinical Pharmacology. 87:1378-1389
Aims To build and verify a physiologically based pharmacokinetic (PBPK) model for radiprodil in adults and link this to a pharmacodynamic (PD) receptor occupancy (RO) model derived from in vitro data. Adapt this model to the paediatric population and
Autor:
Johan Nicolaï, Claude Delatour, Pierre Bonnaillie, Claire Beckers, Kenneth Saunders, Eric Gillent, Marie-Lynn Cuypers, Anna-Lena Ungell, Hugues Chanteux, Sylvie Dell'Aiera
Publikováno v:
Drug Metabolism and Disposition. 48:1121-1128
Early assessment of metabolism pathways of new chemical entities guides the understanding of drug-drug interactions. Selective enzyme inhibitors are indispensable in CYP reaction phenotyping. The most commonly applied CYP2C19 inhibitor, omeprazole, l
Autor:
Sylvie Dell'Aiera, Eric Gillent, Hugues Chanteux, Maria Rosa, Claude Delatour, Johan Nicolaï, Anna-Lena Ungell
Publikováno v:
Drug Metabolism and Disposition. 48:778-787
Early determination of CYP3A4/5 contribution to the clearance of new chemical entities is critical to inform on the risk of drug-drug interactions with CYP3A inhibitors and inducers. Several in vitro approaches (recombinant P450 enzymes, correlation
Despite increased awareness of aldehyde oxidase (AO) as a major drug-metabolising enzyme, predicting the pharmacokinetics of its substrates remains challenging. Several drug candidates have been terminated due to high clearance, which were subsequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d60c6b7a7c6dad272d7f0e8d994190
Autor:
Kenneth Saunders, Hugues Chanteux, Johan Nicolaï, Anna-Lena Ungell, Eric Gillent, Jean-Marie Nicolas, Hélène Chapy
Publikováno v:
Pharmaceutical Research. 37
More accurate prediction of the extent of drug brain exposure in early drug discovery and understanding potential species differences could help to guide medicinal chemistry and avoid unnecessary animal studies. Hence, the aim of the current study wa
Autor:
Benoit Culot, Armel Stockis, E. Bourgogne, Sylvie Dell'Aiera, Jean-Marie Nicolas, Hugues Chanteux
Publikováno v:
Journal of Chromatography B. 1086:138-145
Brivaracetam (BRV) is a new high affinity synaptic vesicle protein 2A ligand recently approved for adults with partial-onset seizures. As a support to in vitro metabolism assays, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method coup
Autor:
Ad F. Roffel, Holly Garratt, Jeff Long, Emma Jones, Eric Helmer, Hugues Chanteux, Tjerk Bosje, Nieves Diaz, Jean-Marie Nicolas
Publikováno v:
The Journal of Clinical Pharmacology. 57:1582-1590
Phosphoinositide 3 kinases are targets for development of small-molecule inhibitors to disrupt progression of immune-inflammatory diseases. This phase 1 open-label study (Eudract 2014-005353-39) evaluated the safety and relative bioavailability of 2